Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Arm Phase II, Multicenter Study of Concomitant Radiotherapy, Tremelimumab and Durvalumab (MEDI4736) for Metastatic or Locally Advanced NSCLC Patients Progressing on First-line Immunotherapy

NCT05000710 is registered in ClinicalTrials.gov with Sheba Medical Center as lead sponsor.

NCT NCT05000710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05000710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Arm Phase II, Multicenter Study of Concomitant Radiotherapy, Tremelimumab and Durvalumab (MEDI4736) for Metastatic or Locally Advanced NSCLC Patients Progressing on First-line Immunotherapy
Lead sponsor
Sheba Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 9, 2021
Completion date
December 31, 2026
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic or locally advanced nsclc